Drug approvals.

2014 FDA drug approvals.



Surrogate Markers and Drug Approvals.

New drug and biological product approvals, 2014.

Neoadjuvant trials could speed up drug approvals.

Discrepancies in drug approvals: A global dilemma.

New drug and biological product approvals, 2013.

Implications of Recent Drug Approvals for Older Adults.

Reply to discrepancies in drug approvals: A global dilemma.

Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.

Therapeutic Leap for Multiple Myeloma in 2015: Unprecedented FDA Drug Approvals.

Current FDA-Related Drug Information: Approvals, Submission, and Important LabelingChanges for US Marketed Pharmaceuticals.

2013 new drug update: what do new approvals hold for the elderly?

A critical appraisal of clinical trials conducted and subsequent drug approvals in India and South Africa.

New drug approvals in acute myeloid leukemia: what's the best end point?

Cross-comparison of cancer drug approvals at three international regulatory agencies.

Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997-2012.

Error in Table Text. Five Years of Cancer Drug Approvals: Innovation Efficacy and Costs.

Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.

Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals.

How physician obesity medicine specialists treated obesity before 2012 new drug approvals.

A review of 2014 cancer drug approvals, with a look at 2015 and beyond.

Postmarketing trials and pediatric device approvals.

2014 FDA drug approvals.

2015 FDA drug approvals.

2013 FDA drug approvals.

Surrogate Markers and Drug Approvals.

New drug and biological product approvals, 2014.

Neoadjuvant trials could speed up drug approvals.

Discrepancies in drug approvals: A global dilemma.

New drug and biological product approvals, 2013.

Implications of Recent Drug Approvals for Older Adults.

Reply to discrepancies in drug approvals: A global dilemma.

Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.

Therapeutic Leap for Multiple Myeloma in 2015: Unprecedented FDA Drug Approvals.

Current FDA-Related Drug Information: Approvals, Submission, and Important LabelingChanges for US Marketed Pharmaceuticals.

2013 new drug update: what do new approvals hold for the elderly?

A critical appraisal of clinical trials conducted and subsequent drug approvals in India and South Africa.

New drug approvals in acute myeloid leukemia: what's the best end point?

Cross-comparison of cancer drug approvals at three international regulatory agencies.

Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997-2012.

Error in Table Text. Five Years of Cancer Drug Approvals: Innovation Efficacy and Costs.

Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.

Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals.

How physician obesity medicine specialists treated obesity before 2012 new drug approvals.

A review of 2014 cancer drug approvals, with a look at 2015 and beyond.

Postmarketing trials and pediatric device approvals.

Drug approvals.

Follow Us

Suggest Documents

2014 FDA drug approvals.

2015 FDA drug approvals.

2013 FDA drug approvals.

Surrogate Markers and Drug Approvals.

New drug and biological product approvals, 2014.

Neoadjuvant trials could speed up drug approvals.

Discrepancies in drug approvals: A global dilemma.

New drug and biological product approvals, 2013.

Implications of Recent Drug Approvals for Older Adults.

Reply to discrepancies in drug approvals: A global dilemma.

Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.

Therapeutic Leap for Multiple Myeloma in 2015: Unprecedented FDA Drug Approvals.

Current FDA-Related Drug Information: Approvals, Submission, and Important LabelingChanges for US Marketed Pharmaceuticals.

2013 new drug update: what do new approvals hold for the elderly?

A critical appraisal of clinical trials conducted and subsequent drug approvals in India and South Africa.

New drug approvals in acute myeloid leukemia: what's the best end point?

Cross-comparison of cancer drug approvals at three international regulatory agencies.

Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997-2012.

Error in Table Text. Five Years of Cancer Drug Approvals: Innovation Efficacy and Costs.

Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.

Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals.

How physician obesity medicine specialists treated obesity before 2012 new drug approvals.

A review of 2014 cancer drug approvals, with a look at 2015 and beyond.

Postmarketing trials and pediatric device approvals.

Drug approvals.

Recommend Documents

Follow Us